Evidence map›Paper›PMID 35884554›Full record

ArticleCancers2022

miRNAs in Serum Exosomes for Differential Diagnosis of Brain Metastases.

Silvia Catelan, Debora Olioso, Alessandra Santangelo, Chiara Scapoli, Anna Tamanini, Giampietro Pinna, Francesco Sala, Giuseppe Lippi, Antonio Nicolato, Giulio Cabrini and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Silvia CatelanSection of Neurosurgery, Department of Neurosciences, Biomedicines and Movement, University of Verona, 37126 Verona, Italy.
Debora OliosoSection of Clinical Biochemistry, Department of Neurosciences, Biomedicines and Movement, University of Verona, 37126 Verona, Italy.ORCID 0000-0002-9048-0364
Alessandra SantangeloSection of Clinical Biochemistry, Department of Neurosciences, Biomedicines and Movement, University of Verona, 37126 Verona, Italy.
Chiara ScapoliDepartment of Life Sciences and Biotechnology, University of Ferrara, 40121 Ferrara, Italy.
Anna TamaniniSection of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, 371234 Verona, Italy.
Giampietro PinnaInstitute of Neurosurgery A, Department of Neurosciences, University Hospital of Verona, 371234 Verona, Italy.
Francesco SalaSection of Neurosurgery, Department of Neurosciences, Biomedicines and Movement, University of Verona, 37126 Verona, Italy.
Giuseppe LippiSection of Clinical Biochemistry, Department of Neurosciences, Biomedicines and Movement, University of Verona, 37126 Verona, Italy.ORCID 0000-0001-9523-9054
Antonio NicolatoSection of Stereotaxy, Department of Neurosciences, University Hospital of Verona, 371234 Verona, Italy.ORCID 0000-0002-1842-8051
Giulio CabriniSection of Clinical Biochemistry, Department of Neurosciences, Biomedicines and Movement, University of Verona, 37126 Verona, Italy.
Maria Cristina DechecchiSection of Clinical Biochemistry, Department of Neurosciences, Biomedicines and Movement, University of Verona, 37126 Verona, Italy.ORCID 0000-0001-7357-2104
University of Verona · ITUniversity of Ferrara · IT

Funding

Brain Research Foundation Verona and FRI not applicable
6 · The paper itself

Abstract

Circulating miRNAs are increasingly studied and proposed as tumor markers with the aim of investigating their role in monitoring the response to therapy as well as the natural evolution of primary or secondary brain tumors. This study aimed to evaluate the modulation of the expression of three miRNAs, miR-21, miR-222 and miR-124-3p, in the serum exosomes of patients with high-grade gliomas (HGGs) and brain metastases (BMs) to verify their usefulness in the differential diagnosis of brain masses; then, it focused on their variations following the surgical and/or radiosurgical treatment of the BMs. A total of 105 patients with BMs from primary lung or breast cancer, or melanoma underwent neurosurgery or radiosurgery treatment, and 91 patients with HGGs were enrolled, along with 30 healthy controls. A significant increase in miR-21 expression in serum exosomes was observed in both HGGs and BMs compared with healthy controls; on the other hand, miR-124-3p was significantly decreased in BMs, and it was increased in HGGs. After the surgical or radiosurgical treatment of patients with BMs, a significant reduction in miR-21 was noted with both types of treatments. This study identified a signature of exosomal miRNAs that could be useful as a noninvasive complementary analysis both in the differential diagnosis of BMs from glial tumors and in providing information on tumor evolution over time.

Indexed as

brain metastasescirculating miRNAsexosomesgamma knife

Identifiers

PMID35884554
PMCPMC9318895
OpenAlexW4285801363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.